Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.51 |
| ▸ | NOS1 | P29475 | 3/20 | 0.51 |
| ▸ | NOS3 | P29474 | 2/20 | 0.51 |
| ▸ | ARG1 | P05089 | 1/20 | 0.48 |
| ▸ | ARG2 | P78540 | 1/20 | 0.48 |
| ▸ | BHMT | Q93088 | 4/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992360 | 0.85 | NOS2 (0.53) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL4992347 | 0.85 | NOS2 (0.53) | NOS2NOS1NOS3ARG1ARG2 | |
| Carbocysteine SCHEMBL19614546 | 0.83 | BHMT (0.57) | NOS2NOS1NOS3ARG1ARG2 | |
| Carbocysteine SCHEMBL19614507 | 0.83 | BHMT (0.57) | NOS2NOS1NOS3ARG1ARG2 | |
| Carbocysteine SCHEMBL19614506 | 0.83 | BHMT (0.57) | NOS2NOS1NOS3ARG1ARG2 | |
| Carbocysteine SCHEMBL15545269 | 0.83 | BHMT (0.57) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL4677572 | 0.83 | ARG1 (0.52) | NOS2NOS1NOS3ARG1ARG2 | |
| Carbocysteine SCHEMBL19614544 | 0.83 | BHMT (0.57) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL10187369 | 0.82 | NOS2 (0.50) | NOS2NOS1NOS3ARG1ARG2 | |
| Carbocysteine SCHEMBL19614528 | 0.81 | BHMT (0.55) | NOS2NOS1NOS3ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217265-B1 | MODIFIED INSULIN POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20100098630-A1 | Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides | AMBRX, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100098630-A1 | Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides | AMBRX, INC. (US) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098630-A1 | Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides | PTMS, NPEPPS, DNPEP | NOS2 386/4885NOS1 955/4885NOS3 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.